Sullivan Lara 4
4 · Pyxis Oncology, Inc. · Filed Apr 2, 2025
Insider Transaction Report
Form 4
Sullivan Lara
DirectorPresident ,CEO & CMO
Transactions
- Award
Stock Option (Right to Buy)
2025-03-31$0.98/sh+918,308$899,942→ 918,308 totalExercise: $0.98Exp: 2035-03-31→ Common Stock (918,308 underlying)
Footnotes (1)
- [F1]The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of March 31,2025 and the remainder vesting in 36 equal monthly instalments thereafter subject to the reporting person's continued employment through the applicable vesting date.